Medivir Narrows Research Strategy To Cancer And Infectious Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Sweden's Medivir drops neuropathic pain research to focus on oncology and infectious diseases while streamlining its R&D process by partnering with India’s GVK BIO, in a bid to cut costs and raise flexibility.